PULMATRIX INC (PULM) Stock Price & Overview
NASDAQ:PULM • US74584P3010
The current stock price of PULM is 2.23 USD. Today PULM is up by 8.78%. In the past month the price decreased by -9.35%. In the past year, price decreased by -73.64%.
PULM Key Statistics
- Market Cap
- 8.14M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.70
- Dividend Yield
- N/A
PULM Stock Performance
PULM Stock Chart
PULM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PULM. When comparing the yearly performance of all stocks, PULM is a bad performer in the overall market: 97.14% of all stocks are doing better.
PULM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PULM. No worries on liquidiy or solvency for PULM as it has an excellent financial health rating, but there are worries on the profitability.
PULM Earnings
PULM Forecast & Estimates
For the next year, analysts expect an EPS growth of -10% and a revenue growth 1% for PULM
PULM Groups
Sector & Classification
PULM Financial Highlights
Over the last trailing twelve months PULM reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS increased by 35.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.85% | ||
| ROE | -131.42% | ||
| Debt/Equity | 0 |
PULM Ownership
PULM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.65 | 951.275B | ||
| JNJ | JOHNSON & JOHNSON | 20.92 | 584.618B | ||
| MRK | MERCK & CO. INC. | 22.63 | 289.542B | ||
| PFE | PFIZER INC | 9.1 | 152.449B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.49 | 123.471B | ||
| ZTS | ZOETIS INC | 17.02 | 51.652B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.9 | 26.443B | ||
| VTRS | VIATRIS INC | 5.61 | 16.373B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.5 | 11.902B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.414B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.72B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.704B | ||
| AMRX | AMNEAL PHARMACEUTICALS INC | 13.69 | 4.169B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PULM
Company Profile
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Company Info
IPO: 2014-03-21
PULMATRIX INC
945 Concord Street, Suite 1217
Framingham MASSACHUSETTS 02421 US
CEO: Teofilo Raad
Employees: 2
Phone: 18883554440
PULMATRIX INC / PULM FAQ
Can you describe the business of PULMATRIX INC?
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Can you provide the latest stock price for PULMATRIX INC?
The current stock price of PULM is 2.23 USD. The price increased by 8.78% in the last trading session.
Does PULMATRIX INC pay dividends?
PULM does not pay a dividend.
What is the ChartMill rating of PULMATRIX INC stock?
PULM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of PULMATRIX INC (PULM)?
PULMATRIX INC (PULM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.7).
Should I buy PULM stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PULM.
How many employees does PULMATRIX INC have?
PULMATRIX INC (PULM) currently has 2 employees.